8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Mar 9, 2026·SEC
Mineralys Therapeutics, Inc.(MLYS)Earnings, Financials & Key Ratios
MLYS•NASDAQ
Price updated Jun 19, 2026
AboutMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Show more
- Revenue$0
- EBITDA-$171M+11.3%
- Net Income-$155M+13.0%
- EPS (Diluted)-2.29+37.4%
- ROE-36.91%+55.1%
MLYS Key Insights
Mineralys Therapeutics, Inc. (MLYS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 114.2% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Shares diluted 39.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MLYS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MLYS Price & Volume
Mineralys Therapeutics, Inc. (MLYS) stock price & volume — 10-year historical chart
Loading chart...
MLYS Growth Metrics
Mineralys Therapeutics, Inc. (MLYS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.04%
Return on Capital
10 Years-349.63%
5 Years-349.63%
3 Years-59.48%
Last Year-40.72%
MLYS Recent Earnings
Mineralys Therapeutics, Inc. (MLYS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.47+7.8%
$0.51
Rev
—
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.40+22.5%
$0.52
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.52+21.2%
$0.66
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.66+15.4%
$0.78
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.47vs $0.51+7.8% | — |
| Q2 2026 | Mar 12, 2026 | $0.40vs $0.52+22.5% | — |
| Q4 2025 | Nov 10, 2025 | $0.52vs $0.66+21.2% | — |
| Q3 2025 | Aug 12, 2025 | $0.66vs $0.78+15.4% | — |
Based on last 12 quarters of dataView full earnings history →
MLYS Peer Comparison
Mineralys Therapeutics, Inc. (MLYS) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CORT | 8.58B | 79.91 | 97.45 | 12.79% | 6.23% | 7.5% | 0.01 | |
 SPRB | 71.84M | 52.36 | -1.03 | -100% | -155.4% | 0.02 | ||
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 MNKD | 1.22B | 3.94 | 197 | 22.23% | -6.63% | |||
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 XOMA | 525.34M | 41.89 | 28.69 | 83.06% | 86.97% | 30.21% | 1.27 | |
 CHRS | 181.17M | 1.48 | -1.02 | -84.2% | -323.49% | -174.71% | 0.66 |
Compare MLYS vs Peers
Mineralys Therapeutics, Inc. (MLYS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MLYS Income Statement
Mineralys Therapeutics, Inc. (MLYS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 21K |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -21K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - |
Operating Expenses | 2.94M | 18.73M | 31.48M | 84.66M | 192.4M | 170.6M | 171.48M |
OpEx % of Revenue | - | - | - | - | - | - | - |
Selling, General & Admin | 532K | 2.42M | 5.23M | 14.3M | 23.82M | 38.59M | 53M |
SG&A % of Revenue | - | - | - | - | - | - | - |
Research & Development | 2.41M | 16.31M | 26.25M | 70.36M | 168.58M | 132.01M | 118.5M |
R&D % of Revenue | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -2.94M▲ 0% | -18.73M▼ 536.3% | -31.48M▼ 68.1% | -84.66M▼ 168.9% | -192.4M▼ 127.3% | -170.6M▲ 11.3% | -171.5M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - |
Operating Income Growth % | - | -536.26% | -68.11% | -168.93% | -127.27% | 11.33% | - |
EBITDA | -3.31M | -19.38M | -31.48M | -84.66M | -192.36M | -170.54M | -171.45M |
EBITDA Margin % | - | - | - | - | - | - | - |
EBITDA Growth % | - | -485.35% | -62.42% | -168.93% | -127.22% | 11.34% | 14.89% |
D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 43K | 59K | 50K |
EBIT | -3.31M | -19.38M | -31.48M | -84.66M | -192.4M | -170.6M | -167.3M |
Net Interest Income | -115K | -27K | 0 | 12.76M | 14.59M | 15.95M | 19.71M |
Interest Income | 0 | 0 | 1.68M | 12.76M | 14.59M | 15.95M | 19.71M |
Interest Expense | 115K | 27K | 1.68M | 0 | 0 | 0 | 0 |
Other Income/Expense | -483K | -683K | 1.68M | 12.76M | 14.59M | 15.95M | 19.72M |
Pretax Income | -3.43M▲ 0% | -19.41M▼ 466.5% | -29.8M▼ 53.5% | -71.9M▼ 141.3% | -177.81M▼ 147.3% | -154.65M▲ 13.0% | -151.78M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -3.43M▲ 0% | -19.41M▼ 466.5% | -29.8M▼ 53.5% | -71.9M▼ 141.3% | -177.81M▼ 147.3% | -154.65M▲ 13.0% | -151.78M▲ 0% |
Net Margin % | - | - | - | - | - | - | - |
Net Income Growth % | - | -466.49% | -53.54% | -141.28% | -147.31% | 13.02% | 19.49% |
Net Income (Continuing) | -3.43M | -19.41M | -29.8M | -71.9M | -177.81M | -154.65M | -151.78M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.74▲ 0% | -3.89▼ 425.7% | -5.77▼ 48.3% | -1.99▲ 65.5% | -3.66▼ 83.9% | -2.29▲ 37.4% | -1.83▲ 0% |
EPS Growth % | - | -425.68% | -48.33% | 65.51% | -83.92% | 37.43% | 45.04% |
EPS (Basic) | -0.74 | -3.89 | -5.77 | -1.99 | -3.66 | -2.29 | - |
Diluted Shares Outstanding | 4.63M | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M | 82.83M |
Basic Shares Outstanding | 4.63M | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M | 82.83M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
MLYS Balance Sheet
Mineralys Therapeutics, Inc. (MLYS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 1.47M | 11.12M | 112.81M | 249.1M | 205.35M | 661.39M | 652.47M |
Cash & Short-Term Investments | 1.41M | 10.61M | 110.11M | 236.57M | 198.19M | 656.63M | 646.06M |
Cash Only | 1.41M | 10.61M | 87.7M | 49.3M | 114.09M | 172.92M | 112.78M |
Short-Term Investments | 0 | 0 | 22.41M | 187.26M | 84.1M | 483.71M | 533.28M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.7M | 12.54M | 7.16M | 4.75M | 6.41M |
Total Non-Current Assets | 20K | 3K | 1.63M | 2.53M | 552K | 420K | 392K |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 53K | 38K | 32K |
Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 2.48M | 0 | 0 | 0 |
Other Non-Current Assets | 20K | 3K | 1.63M | 51K | 499K | 382K | 360K |
Total Assets | 1.49M▲ 0% | 11.13M▲ 648.7% | 114.44M▲ 928.7% | 251.64M▲ 119.9% | 205.9M▼ 18.2% | 661.81M▲ 221.4% | 652.86M▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 648.65% | 928.69% | 119.88% | -18.17% | 221.42% | 434.41% |
Total Current Liabilities | 5.08M | 5.05M | 8.07M | 10.48M | 14.65M | 15.11M | 14.72M |
Accounts Payable | 529K | 763K | 1.91M | 601K | 479K | 2.02M | 1.12M |
Days Payables Outstanding | - | - | - | - | - | - | 32.23K |
Short-Term Debt | 4.5M | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 313K | 665K | 1.6M | 0 | 7.56M | 11.29M |
Current Ratio | 0.29x | 2.20x | 13.98x | 23.76x | 14.02x | 43.76x | 44.33x |
Quick Ratio | 0.29x | 2.20x | 13.98x | 23.76x | 14.02x | 43.76x | 44.33x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 29M | 158.64M | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 29M | 158.64M | 0 | 0 | 0 | 0 |
Total Liabilities | 5.08M | 34.05M | 166.71M | 10.48M | 14.65M | 15.11M | 14.72M |
Total Debt | 4.5M | 0 | 0 | 0 | 0 | 0 | 0 |
Net Debt | 3.09M | -10.61M | -87.7M | -49.3M | -114.09M | -172.92M | -112.78M |
Debt / Equity | - | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.66x |
Interest Coverage | -28.79x | -717.81x | -18.78x | - | - | - | - |
Total Equity | -3.6M▲ 0% | -22.93M▼ 537.3% | -52.27M▼ 128.0% | 241.15M▲ 561.4% | 191.26M▼ 20.7% | 646.69M▲ 238.1% | 638.14M▲ 0% |
Equity Growth % | - | -537.34% | -128% | 561.37% | -20.69% | 238.13% | 476.34% |
Book Value per Share | -0.78 | -4.60 | -10.12 | 6.66 | 3.94 | 9.56 | 7.70 |
Total Shareholders' Equity | -3.6M | -22.93M | -52.27M | 241.15M | 191.26M | 646.69M | 638.14M |
Common Stock | 1K | 1K | 1K | 4K | 5K | 8K | 8K |
Retained Earnings | -3.6M | -23.01M | -52.81M | -124.71M | -302.52M | -457.17M | -496.51M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | -251.64M | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MLYS Cash Flow Statement
Mineralys Therapeutics, Inc. (MLYS) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -2.46M | -14.56M | -29.22M | -81.17M | -166.31M | -142.42M | -136.4M |
Operating CF Margin % | - | - | - | - | - | - | - |
Operating CF Growth % | - | -491.11% | -100.71% | -177.79% | -104.89% | 14.37% | 98.94% |
Net Income | -3.43M | -19.41M | -29.8M | -71.9M | -177.81M | -154.65M | -151.78M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 43K | 59K | 50K |
Stock-Based Compensation | 1K | 80K | 455K | 5.06M | 11.34M | 19.32M | 15.68M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 482K | 684K | -649K | -6.87M | -9.4M | -9.88M | -6.91M |
Working Capital Changes | 480K | 4.08M | 772K | -7.47M | 9.52M | 2.73M | 6.56M |
Change in Receivables | 0 | 0 | 0 | -355K | 424K | -166K | 71K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | 0 | 0 | -21.76M | -160.47M | 114.96M | -389.75M | -341.82M |
Capital Expenditures | 0 | 0 | 0 | 0 | -96K | -15K | -15K |
CapEx % of Revenue | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 3.83M | 23.81M | 128.02M | 203.25M | 116.14M | 591M | 425.99M |
Debt Issued (Net) | 3.85M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | -20K | 23.81M | 128.02M | 202.99M | 116.06M | 591M | 419.4M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -1.63M | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 258K | 83K | 0 | 6.59M |
Net Change in Cash | 1.41M▲ 0% | 9.25M▲ 556.7% | 77.04M▲ 732.6% | -38.4M▼ 149.8% | 64.79M▲ 268.7% | 58.83M▼ 9.2% | -52.23M▲ 0% |
Free Cash Flow | -2.46M▲ 0% | -14.56M▼ 491.1% | -29.22M▼ 100.7% | -81.17M▼ 177.8% | -166.41M▼ 105.0% | -142.43M▲ 14.4% | -136.41M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - |
FCF Growth % | - | -491.11% | -100.71% | -177.79% | -105.01% | 14.41% | 29.21% |
FCF per Share | -0.53 | -2.92 | -5.65 | -2.24 | -3.43 | -2.11 | -1.65 |
FCF Conversion (FCF/Net Income) | 0.72x | 0.75x | 0.98x | 1.13x | 0.94x | 0.92x | 0.90x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MLYS Key Ratios
Mineralys Therapeutics, Inc. (MLYS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -76.13% | -82.24% | -36.91% | -27.92% |
Return on Invested Capital (ROIC) | - | - | -244.77% | -107.28% | -46.45% | -32.78% |
Debt / Equity | - | - | - | - | - | 0.00x |
Interest Coverage | -717.81x | -18.78x | - | - | - | - |
FCF Conversion | 0.75x | 0.98x | 1.13x | 0.94x | 0.92x | 0.90x |
Related:MLYS Dividend History·MLYS Revenue History·MLYS Price History·MLYS P/E History·MLYS Financial Ratios·MLYS Institutional Holders
MLYS SEC Filings & Documents
Mineralys Therapeutics, Inc. (MLYS) SEC filings — annual & quarterly reports (10-K, 10-Q)
MLYS Frequently Asked Questions
Mineralys Therapeutics, Inc. (MLYS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mineralys Therapeutics, Inc. (MLYS) grew revenue by 0.0% over the past year. Growth has been modest.
Mineralys Therapeutics, Inc. (MLYS) reported a net loss of $151.8M for fiscal year 2025.
Dividend & Returns
Mineralys Therapeutics, Inc. (MLYS) has a return on equity (ROE) of -36.9%. Negative ROE indicates the company is unprofitable.
Mineralys Therapeutics, Inc. (MLYS) had negative free cash flow of $136.4M in fiscal year 2025, likely due to heavy capital investments.